and attempts may also be made to enhance the effects of cancer treatment using immune cells such as T cells and natural killer (NK) cells. The CAR-NK cell therapy ‘TAK-007’ developed by Takeda ...

CytoMed has generated the critical cell banks for the iPSC-derived hybrid of gamma delta T and Natural Killer cell technology and is currently undergoing process development into a potentially very ...

Capitalizing on Asia’s low-cost infrastructure and talents, we make affordable GMP-grade immune ... manufacturing cord blood-derived Natural Killer cells, widely researched for its safe and ...

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company") today released a letter to shareholders from the Chairman of the Company's Board ...

marking the group's first assessment of allogeneic induced pluripotent stem cell (iPSC)-derived CD19-directed NK cell therapy in this domain. The Schett/Mackensen group, known for their pioneering ...

Defining a consistent product is inherently challenging because of the very characteristics that make pluripotent stem cells attractive as a source of therapeutic cells. Pluripotent stem cells are ...

Personalized medicine advances as autologous cell therapy grows, leveraging refined cell collection, improved processing ...

Commissioning key for India-made solar cells Indian domestic solar cell production capacity is expected to increase more than fourfold to between 43 GW and 47 GW by June 2026, up from 10 GW in ...

The two companies will collaborate on the development of targeted NK cell and macrophage cells derived from induced pluripotent stem cells (iPSC), cementing a relationship that has already seen ...

This is the first study conducted by the internationally recognized Schett/Mackensen group to explore allogeneic induced pluripotent stem cells (iPSCs) derived CD19-directed Natural Killer (NK) cell ...